OPTIMA

Optimal treatment for patients with solid tumours in Europe through artificial intelligence

Summary

Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of diagnostic tests, treatments and guidelines, making it increasingly challenging to ensure each patient receives the right treatment.

The aim of OPTIMA is to harness the power of artificial intelligence to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer.

At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data and evidence generation platform with data from over 200 million people. The platform, which will be GDPR (General Data Protection Regulation) compliant, will host data sets, data analysis tools, federated learning tools, and artificial intelligence (AI) tools.

The project will use the platform to drive the generation of new knowledge by developing advanced analytics and AI models to identify, prioritise and fill the main knowledge gaps in prostate, breast and lung cancer, and propose improved clinical guideline recommendations. Finally, they will develop AI-based decision support tools that can help clinicians, together with their patients, make treatment decisions based on the leading clinical practice guidelines.

By designing the platform based on the needs of clinicians and patients, and by including the major guideline offices for prostate, breast and lung cancer, the project is well placed to have an impact care down the line.

Achievements & News

Participants

  Show participants on map
EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Amgen, Brussels, Belgium
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Association Eisbm, Vourles, France
  • Deutsche Krebsgesellschaft Ev, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium
  • European Respiratory Society, Lausanne, Switzerland
  • Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
  • Helmholtz-Zentrum Dresden-Rossendorf Ev, Dresden, Germany
  • Institut De Cancerologie De L'Ouest, Angers, France
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Lunds Universitet, Lund, Sweden
  • Queen Mary University Of London, London, United Kingdom
  • Region Uppsala, Uppsala, Sweden
  • Tartu Ulikool, Tartu, Estonia
  • The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitat Wien, Vienna, Austria
  • Universiteit Maastricht, Maastricht, Netherlands
  • University College London, London, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic Innovation GMBH, Munchen, Germany
  • Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
  • Istituto Europeo Di Oncologia SRL, Milan, Italy
  • Mutabor Technologies GMBH, Hamburg, Germany
  • Owkin France, Paris, France
  • Smart Reporting GMBH, München, Germany
  • Stichting European Urological Foundation, Arnhem, Netherlands
  • Ttopstart BV, Bilthoven, Netherlands
  • Ydeal.Net Software Lda, Santa Maria da Feira, Portugal
Patient organisations
  • European Lung Foundation, Sheffield, United Kingdom
Third parties
  • Lungs Europe, Brussels, Belgium
Non EFPIA companies
  • Helios Klinikum Emil Von Behring GMBH, Berlin, Germany

Participants
NameEU funding in €
Arttic Innovation GMBH162 857
Association Eisbm884 000
Deutsche Krebsgesellschaft Ev99 993
Erasmus Universitair Medisch Centrum Rotterdam575 259
European Cancer Patient Coalition (left the project)24 843
European Lung Foundation118 803
European Organisation For Research And Treatment Of Cancer Aisbl75 001
European Respiratory Society126 750
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina200 416
Gmv Soluciones Globales Internet Sau744 353
Helmholtz-Zentrum Dresden-Rossendorf Ev684 000
Information Technology For Translational Medicine (Ittm) SA787 500
Institut De Cancerologie De L'Ouest90 000
Istituto Europeo Di Oncologia SRL50 000
Ludwig-Maximilians-Universitaet Muenchen40 000
Lunds Universitet71 000
Owkin France299 962
Queen Mary University Of London220 000
Region Uppsala483 000
Smart Reporting GMBH398 250
Stichting European Urological Foundation822 280
Tartu Ulikool470 000
The University Court Of The University Of Aberdeen613 424
Ttopstart BV326 218
Universita Vita-Salute San Raffaele50 125
Universitat Wien433 130
Universiteit Maastricht300 000
University College London98 590
University of Oxford967 594
Uppsala Universitet67 875
Ydeal.Net Software Lda162 275
 
Third parties
NameFunding in €
Lungs Europe12 500
 
Total Cost10 459 998